Clinical Trials Arena March 18, 2024
Nottingham University spin-out Neupulse is targeting regulatory applications in the UK, Europe, and US for its device following positive clinical data.
Neupulse, a UK-based company that is developing a wristband to help manage the symptoms of Tourette’s syndrome, has raised $3.2m in seed financing.
The trade name of Neurotherapeutics Limited, Neupulse spun out from the University of Nottingham in 2021 following positive research into managing tics by electrical stimulation.
The company has developed a wearable device that stimulates the median nerve in the wrist. Neupulse says that the prototype can reduce tic frequency and severity.
A Neupulse spokesperson told Medical Device Network the funding will be used “to finalise the prototype and start our regulatory applications.
“We are currently developing...
Today's Sponsors
Today's Sponsor